Maribavir for treating refractory cytomegalovirus infection after transplant

    Année de publication: 2023

    Evidence-based recommendations on maribavir (Livtencity) for cytomegalovirus infection in adults after transplant. Commercial arrangement There is a simple discount patient access scheme for maribavir. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact smb.marketaccessUK@takeda.com for details.